Short-course antibiotic treatment of bone and joint infections in children: a retrospective study at Montpellier University Hospital from 2009 to 2013.


Journal

The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617

Informations de publication

Date de publication:
01 12 2019
Historique:
received: 01 02 2019
revised: 16 07 2019
accepted: 18 07 2019
pubmed: 11 9 2019
medline: 26 9 2020
entrez: 11 9 2019
Statut: ppublish

Résumé

Acute haematogenous bone and joint infections (AHBJI) represent a diagnostic and therapeutic emergency in children, with significant potential sequelae in the case of delayed treatment. Although historically the recommendations for treatment have been based on surgery and prolonged antibiotic therapy, recent studies have demonstrated that short-course antibiotic therapy is also effective. We evaluated a short-term antibiotic protocol for both osteomyelitis and septic arthritis in a 6 year retrospective study at the University Hospital of Montpellier. This protocol was based on an initial intravenous treatment with a re-evaluation after 48 h and an early switch to oral therapy in the case of a favourable clinical course for a minimum total duration of 15 days. Antibiotics were selected based on local microbiological epidemiology and systematically adapted to bacteriological results. One hundred and seventy-six cases of AHBJI were included, comprising 56 patients with osteomyelitis, 95 with septic arthritis and 25 who had both of these. The aetiological agent was identified in 42% of the cases, with the main pathogens being Staphylococcus aureus (39%) and Kingella kingae (27%). The mean intravenous treatment duration was 4 days, while the total treatment duration was 15 days. There were no treatment failures, mild sequelae occurred in 1% of the cases and the secondary surgical revision rate was 7%. The results of this study are comparable to those reported for evaluations of prolonged antibiotic therapy protocols, thus indicating that a common short-term antimicrobial therapy for the management of both osteomyelitis and septic arthritis (minimum of 15 days) is a viable option for treating AHBJI in children. Further prospective studies to confirm these findings are hence warranted.

Sections du résumé

BACKGROUND
Acute haematogenous bone and joint infections (AHBJI) represent a diagnostic and therapeutic emergency in children, with significant potential sequelae in the case of delayed treatment. Although historically the recommendations for treatment have been based on surgery and prolonged antibiotic therapy, recent studies have demonstrated that short-course antibiotic therapy is also effective.
OBJECTIVES
We evaluated a short-term antibiotic protocol for both osteomyelitis and septic arthritis in a 6 year retrospective study at the University Hospital of Montpellier.
METHODS
This protocol was based on an initial intravenous treatment with a re-evaluation after 48 h and an early switch to oral therapy in the case of a favourable clinical course for a minimum total duration of 15 days. Antibiotics were selected based on local microbiological epidemiology and systematically adapted to bacteriological results.
RESULTS
One hundred and seventy-six cases of AHBJI were included, comprising 56 patients with osteomyelitis, 95 with septic arthritis and 25 who had both of these. The aetiological agent was identified in 42% of the cases, with the main pathogens being Staphylococcus aureus (39%) and Kingella kingae (27%). The mean intravenous treatment duration was 4 days, while the total treatment duration was 15 days. There were no treatment failures, mild sequelae occurred in 1% of the cases and the secondary surgical revision rate was 7%.
CONCLUSIONS
The results of this study are comparable to those reported for evaluations of prolonged antibiotic therapy protocols, thus indicating that a common short-term antimicrobial therapy for the management of both osteomyelitis and septic arthritis (minimum of 15 days) is a viable option for treating AHBJI in children. Further prospective studies to confirm these findings are hence warranted.

Identifiants

pubmed: 31504582
pii: 5559581
doi: 10.1093/jac/dkz358
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3579-3587

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

A Filleron (A)

Service de pédiatrie, CHU de Nîmes, Nîmes, France; INSERM U 1183, Université Montpellier-Nîmes, Nîmes, France.

M E Laurens (ME)

Département de pédiatrie néonatale et de réanimation, CHU de Montpellier, Montpellier, France.

G Marin (G)

Department d'Information Medicale, CHU Montpellier, Montpellier, France.

H Marchandin (H)

HydroSciences Montpellier, University of Montpellier, CNRS, IRD, Montpellier, France; Laboratoire de microbiologie, CHU Nîmes, Nîmes, France.

O Prodhomme (O)

Département d'imagerie pédiatrique, CHU de Montpellier, Montpellier, France.

F Alkar (F)

Service de chirurgie orthopédique infantile, CHU Montpellier, Montpellier, France.

S Godreuil (S)

Service de bactériologie, CHU Montpellier, Montpellier, France.
Université de Montpellier UMR MIVEGEC, UMR IRD 224-CNRS Inserm, 1058, Montpellier, France.

N Nagot (N)

Department d'Information Medicale, CHU Montpellier, Montpellier, France.
Pathogenesis and Control of Chronic Infections, INSERM, Université de Montpellier, Montpellier, France.

J Cottalorda (J)

Service de chirurgie orthopédique infantile, CHU Montpellier, Montpellier, France.

M L'Kaissi (M)

Service de chirurgie infantile, CHU de la réunion, Saint-Denis, France.

M Rodiere (M)

Département urgences post-urgences, CHU Montpellier, Montpellier, France.

M G Vigue (MG)

Département urgences post-urgences, CHU Montpellier, Montpellier, France.

M N Didelot (MN)

Service de bactériologie, CHU Montpellier, Montpellier, France.
Pathogenesis and Control of Chronic Infections, INSERM, Université de Montpellier, Montpellier, France.

A L Michon (AL)

Service de bactériologie, CHU Montpellier, Montpellier, France.

M Delpont (M)

Service de chirurgie orthopédique infantile, CHU Montpellier, Montpellier, France.

D Louahem (D)

Service de chirurgie orthopédique infantile, CHU Montpellier, Montpellier, France.

E Jeziorski (E)

Pathogenesis and Control of Chronic Infections, INSERM, Université de Montpellier, Montpellier, France.
Département urgences post-urgences, CHU Montpellier, Montpellier, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH